Literature DB >> 15921738

Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel.

Christoph Buchta1, Hans Christian Hedrich, Maria Macher, Paul Höcker, Heinz Redl.   

Abstract

Different principles for production of "autologous fibrin sealant" have been established, and commercial devices employing these methods are nowadays available and used in clinical routine. Users might anticipate for these autologous fibrin sealants features comparable to commercial homologous fibrin sealants, used in surgical routine for many years. However, only little is known about biochemical properties, formation, cross-linking and stability of fibrin sealant clots produced for autologous use with the aid of commercially available devices. We have investigated protein composition, formation and stability of clots obtained from autologuous fibrin sealants produced with commercially available devices (CryoSeal and Vivostat) and compared these parameters to those of the industrially produced homologous fibrin sealant Tissucol/Tisseel. The CryoSeal product is a mixture of many plasma proteins; the Vivostat product and Tissucol/Tisseel appear as comparatively pure plasma derivatives. The products differ in their protein composition and concentrations, including their concentration in fibrin. Significant fibrin alpha and gamma-chain cross-linking by FXIIIa occurs only in Tissucol/Tisseel clots. In test tubes CryoSeal and Vivostat (tranexamic acid-free formulation) fibrin clots liquefy within 1-2 days, but Vivostat (tranexamic acid containing formulation) clots were stable for 4 days and showed partial liquefaction after 5 days. Tissucol/Tisseel clots, containing the protease inhibitor aprotinin, appeared unchanged over the observation period of 5 days. In an in vitro model mimicking in vivo conditions (diffusion of protease inhibitors and proteolytic digestion) clot liquefaction occurs at day 1 for all autologous fibrin sealants clots, with an observable delay for the tranexamic acid containing Vivostat, and day 5 for Tissucol/Tisseel clots. Characterization of the CryoSeal and Vivostat fibrin sealants and Tissucol/Tisseel and their performance show a clear difference in biochemical properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921738     DOI: 10.1016/j.biomaterials.2005.04.014

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  29 in total

1.  Augmentation of postswelling surgical sealant potential of adhesive hydrogels.

Authors:  Tarek M Shazly; Aaron B Baker; John R Naber; Adriana Bon; Krystyn J Van Vliet; Elazer R Edelman
Journal:  J Biomed Mater Res A       Date:  2010-09-28       Impact factor: 4.396

Review 2.  Fibrin gels and their clinical and bioengineering applications.

Authors:  Paul A Janmey; Jessamine P Winer; John W Weisel
Journal:  J R Soc Interface       Date:  2009-01-06       Impact factor: 4.118

3.  Viscoelastic adhesive mechanics of aldehyde-mediated soft tissue sealants.

Authors:  Tarek M Shazly; Natalie Artzi; Fiete Boehning; Elazer R Edelman
Journal:  Biomaterials       Date:  2008-09-19       Impact factor: 12.479

4.  Temporal and spatial patterning of transgene expression by near-infrared irradiation.

Authors:  Francisco M Martin-Saavedra; Virginia Cebrian; Leyre Gomez; Daniel Lopez; Manuel Arruebo; Christopher G Wilson; Renny T Franceschi; Richard Voellmy; Jesus Santamaria; Nuria Vilaboa
Journal:  Biomaterials       Date:  2014-06-21       Impact factor: 12.479

5.  7 Procoagulators.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 6.  Protein based therapeutic delivery agents: Contemporary developments and challenges.

Authors:  Liming Yin; Carlo Yuvienco; Jin Kim Montclare
Journal:  Biomaterials       Date:  2017-04-21       Impact factor: 12.479

7.  Vivostat®: an autologous fibrin sealant as useful adjunct in endoscopic transnasal CSF-leak repair.

Authors:  Peter Valentin Tomazic; Stefan Edlinger; Verena Gellner; Wolfgang Koele; Claus Gerstenberger; Hannes Braun; Michael Mokry; Heinz Stammberger
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-08       Impact factor: 2.503

8.  Concentration of fibrin and presence of plasminogen affect proliferation, fibrinolytic activity, and morphology of human fibroblasts and keratinocytes in 3D fibrin constructs.

Authors:  Erik Reinertsen; Michael Skinner; Benjamin Wu; Bill Tawil
Journal:  Tissue Eng Part A       Date:  2014-05-27       Impact factor: 3.845

9.  Optimization of fibrin scaffolds for differentiation of murine embryonic stem cells into neural lineage cells.

Authors:  Stephanie M Willerth; Kelly J Arendas; David I Gottlieb; Shelly Elese Sakiyama-Elbert
Journal:  Biomaterials       Date:  2006-08-17       Impact factor: 12.479

Review 10.  Fibrin glue in ophthalmology.

Authors:  Anita Panda; Sandeep Kumar; Abhiyan Kumar; Raseena Bansal; Shibal Bhartiya
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.